BRPI0418255A - unsubstituted piperazine and piperidine derivatives - Google Patents

unsubstituted piperazine and piperidine derivatives

Info

Publication number
BRPI0418255A
BRPI0418255A BRPI0418255-3A BRPI0418255A BRPI0418255A BR PI0418255 A BRPI0418255 A BR PI0418255A BR PI0418255 A BRPI0418255 A BR PI0418255A BR PI0418255 A BRPI0418255 A BR PI0418255A
Authority
BR
Brazil
Prior art keywords
piperidine derivatives
unsubstituted piperazine
piperazine
disorders
unsubstituted
Prior art date
Application number
BRPI0418255-3A
Other languages
Portuguese (pt)
Inventor
Stephen Sung Yong Cho
Tracy Fay Gregory
Peter Robert Guzzo
Harry Ralph Howard Jr
Sham Shridhar Nikam
Matthew David Surman
Michael Anthony Walters
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0418255A publication Critical patent/BRPI0418255A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADOS DE PIPERAZINA E PIPERIDINA N-SUBSTITUìDOS". Esta invenção se relaciona com compostos de fórmula 1, em que R¬ 1¬, R¬ 2¬, R¬ 7¬, R¬ 8¬, R¬ 9¬, U, V, Z, A, W, X, M, E, L, T e D são definidos conforme a especificação, composições farmacêuticas que os contêm e uso deles no tratamento de distúrbios do sistema nervoso central e de outros distúrbios."N-REPLACED PIPERAZINE AND PIPERIDINE DERIVATIVES". This invention relates to compounds of formula 1 wherein R¬1¬, R¬2¬, R¬7¬, R¬8 V, R¬9¬, U, V, Z, A, W, X, M , E, L, T and D are defined according to the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders and other disorders.

BRPI0418255-3A 2003-12-31 2004-12-20 unsubstituted piperazine and piperidine derivatives BRPI0418255A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53376103P 2003-12-31 2003-12-31
PCT/IB2004/004239 WO2005066165A1 (en) 2003-12-31 2004-12-20 N-substituted piperidine and piperazine derivatives

Publications (1)

Publication Number Publication Date
BRPI0418255A true BRPI0418255A (en) 2007-04-17

Family

ID=34748954

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418255-3A BRPI0418255A (en) 2003-12-31 2004-12-20 unsubstituted piperazine and piperidine derivatives

Country Status (6)

Country Link
EP (1) EP1701954A1 (en)
JP (1) JP2007517014A (en)
BR (1) BRPI0418255A (en)
CA (1) CA2551346A1 (en)
MX (1) MXPA06007654A (en)
WO (1) WO2005066165A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560814A1 (en) * 2002-11-13 2005-08-10 Synthon B.V. Process for making risperidone and intermediates therefor
WO2008020306A2 (en) * 2006-08-18 2008-02-21 Pfizer Products Inc. Isoindole derivatives
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP5732453B2 (en) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Prodrugs of NH acidic compounds
PT2445502T (en) 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
CN102884059B (en) * 2010-03-11 2015-08-26 大日本住友制药株式会社 N-acyl cyclic amine derivatives or pharmaceutically acceptable salts thereof
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
ES2972387T3 (en) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising sorbitan esters
JP5715605B2 (en) * 2011-09-14 2015-05-07 大日本住友製薬株式会社 Pharmaceutical comprising N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
JP6654042B2 (en) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition with improved storage stability
BR122019007990B1 (en) 2013-11-18 2021-05-04 Forma Therapeutics, Inc COMPOUND, AND, PHARMACEUTICAL COMPOSITION
RU2720237C2 (en) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Compositions containing benzopiperazine as bromodomain bet inhibitors
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2023051753A1 (en) * 2021-09-30 2023-04-06 武汉朗来科技发展有限公司 Preparation method for rock inhibitor, intermediate thereof and preparation method for intermediate
CN115894325B (en) * 2022-09-20 2025-05-27 徐州医科大学 Derivative containing aryl piperazine structure, composition and application thereof
CN115521302B (en) * 2022-09-20 2025-03-21 徐州医科大学 A tetrahydro(iso)quinoline or indoline derivative, composition and application thereof
CN115433116B (en) * 2022-09-20 2023-07-14 徐州医科大学 Acylated indoline derivatives, composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
EA200500342A1 (en) * 2002-09-17 2005-08-25 УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си HETEROCYCLIC SUBSTITUTED PIPERASINES FOR THE TREATMENT OF SCHIZOPHRENIA
PL376721A1 (en) * 2002-10-24 2006-01-09 Pfizer Products Inc. Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity

Also Published As

Publication number Publication date
CA2551346A1 (en) 2005-07-21
WO2005066165A1 (en) 2005-07-21
JP2007517014A (en) 2007-06-28
EP1701954A1 (en) 2006-09-20
MXPA06007654A (en) 2006-09-04

Similar Documents

Publication Publication Date Title
BR0208338A (en) Pyridine Derivatives
BR0314393A (en) Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia
BRPI0413860A (en) [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia.
BR0312560A (en) New tricyclic spiropiperidines or spiropyrrolidines
BRPI0510453A (en) Substituted Morpholine Compounds for the Treatment of Central Nervous System Disorders
BR0016396A (en) New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
BR0316350A (en) Diaminotriazoles useful as protein kinase inhibitors
BR0113838A (en) N-phenyl-2-pyrimidine amine derivatives
BR0310077A (en) New compounds and their use
BR0108678A (en) New compounds
SE0001899D0 (en) New compounds
BR0016543A (en) New piperidine and piperazine derivatives
BRPI0215312B8 (en) compound, use of a compound, pharmaceutical composition, and process for preparing a compound
SE9904505D0 (en) Novel compounds
BR0208741A (en) Piperidine Derivatives
BRPI0413094A (en) quinoline derivatives and their use in therapy
BRPI0414948A (en) pyrazolo-e-imidazo pyrimidine derivatives
NO20020282L (en) New diphenyl-piperidine derivative
BR0313385A (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
DE602004031410D1 (en) INDIVIDUAL DERIVATIVES AS PHARMACEUTICALS
SE9903894D0 (en) Novel compounds
BR0316108A (en) Phenylalkyl and pyridylalkyl piperazine derivatives and pharmaceutical composition comprising them
BR0213037A (en) Pyrimidine Derivatives
BR0314796A (en) Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia
BR0103048A (en) N-triazolylmethyl-piperazine derivatives as neurokinin receptor antagonists

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.